Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C42H57ClN4O5S |
| Molecular Weight | 765.444 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@]3(CN1CC[N@]2CCCC[C@@H]2C1)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C4=CC=C5OC[C@]6(CCCC7=CC(Cl)=CC=C67)CN(C[C@@H]8CC[C@@H]38)C5=C4
InChI
InChIKey=BJTFTQIBRVBSBH-VCQPVEJUSA-N
InChI=1S/C42H57ClN4O5S/c1-29-8-6-18-42(51-3,27-45-20-21-46-19-5-4-10-35(46)25-45)37-14-11-33(37)24-47-26-41(17-7-9-31-22-34(43)13-15-36(31)41)28-52-39-16-12-32(23-38(39)47)40(48)44-53(49,50)30(29)2/h6,12-13,15-16,18,22-23,29-30,33,35,37H,4-5,7-11,14,17,19-21,24-28H2,1-3H3,(H,44,48)/b18-6+/t29-,30+,33-,35+,37+,41-,42-/m0/s1
| Molecular Formula | C42H57ClN4O5S |
| Molecular Weight | 765.444 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 22:10:46 GMT 2025
by
admin
on
Tue Apr 01 22:10:46 GMT 2025
|
| Record UNII |
BO0V7196L2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
675018
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
||
|
FDA ORPHAN DRUG |
698019
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
||
|
FDA ORPHAN DRUG |
674818
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
138669688
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
PRIMARY | |||
|
C156740
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
PRIMARY | |||
|
HI-235
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
PRIMARY | |||
|
300000024168
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
PRIMARY | |||
|
2245848-05-7
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
PRIMARY | |||
|
BO0V7196L2
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
PRIMARY | |||
|
11281
Created by
admin on Tue Apr 01 22:10:46 GMT 2025 , Edited by admin on Tue Apr 01 22:10:46 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
|
TARGET -> INHIBITOR |
In-vitro, AMG 397 neutralizes the interaction between the human anti-apoptotic MCL1 – (BIM) in a time-resolved fluorescence resonance energy transfer-based assay with a mean half-maximal inhibitory concentration (IC50) of 0.116 nM
IC50
|
||
|
|
TRANSPORTER -> SUBSTRATE |
Efflux ratio of 100 at 1?M versus 4 with Pg-p inhibitor
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |